Over the last 12 months, one Ensysce Biosciences, Inc. insiders picked up shares on the open market, about $444,000 in total, and none of them sold.
GOWER BOB G (Director) made the biggest buy, worth around $244,000.
Zooming out by quarter: 2 quarters in a row of net buying by insiders. Insiders bought in 2 of the last 7 full quarters. 18 investment managers listed ENSC in their latest 13F filings (Q2 2026); more funds bought than sold.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 18, 2026 | GOWER BOB G | Director | Buy | 400,000 | $0.50 | $200K | SEC |
| Aug 18, 2026 | GOWER BOB G | Director | Buy | 508,614 | $0.48 | $244K | SEC |
| Mar 6, 2023 | GOWER BOB G | Director | Buy | 90,287 | $0.49 | $44K | SEC |
| Mar 2, 2023 | GOWER BOB G | Director | Buy | 109,300 | $0.49 | $54K | SEC |
| Mar 2, 2023 | GOWER BOB G | Director | Buy | 270,000 | $0.48 | $130K | SEC |
| Feb 1, 2023 | GOWER BOB G | Director | Buy | 357,143 | $1.40 | $500K | SEC |
In the last 12 months Ensysce Biosciences, Inc. insiders made open-market purchases worth about $444,000 and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in ENSC was filed on 2026-08-18.
18 investment managers reported holding ENSC in SEC Form 13F filings for Q2 2026.
No congressional trades in ENSC were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).